Skip to content
Head to head

Eton Pharmaceutical vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: ETON · TAK

Updated 3 minutes ago

1-year performance, rebased to 100

ETON +252.5%TAK +56.6%
Eton Pharmaceutical edges it on the scoreable measures. Eton Pharmaceutical has the highest Quant Rating (100); Eton Pharmaceutical has done best over the past year (+273%); Eton Pharmaceutical trades cheapest on trailing earnings.
ETONTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price60.8521.77
Change today-0.83%+1.68%
1-year return+273.3%+57.5%
Market cap$1.76B$69.76B
52-week range14.27 – 70.6413.92 – 22.07
Valuation
P/E (TTM)39.51311.00
P/E percentile, own 5-yr range85th100th
P/B20.191.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.17-0.30
Net profit (TTM)$-4.90M$-970.94M
Revenue (TTM)$141.06M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+157.9%+6.7%
Gross margin69.2%65.8%
Operating margin28.8%14.3%
Net margin35.3%0.9%
Free cash flow (TTM)$19.99M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership74.2%51.3%
Insider activity (12mo)24 buy / 21 sell19 buy / 31 sell
Short interest (% of float)6.9%0.1%
Analyst consensus100% buy (4)100% buy (1)
Analyst price target$81 (+33%)$50 (+132%)
StockVane view
StockVane Quant RatingC (100)C (90)
Company
Employees4447,029
Founded20171781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.